Treatment of obesity with medications binding the glucagon-like peptide 1 receptor: what is the current state of play?

References

• Obesity Atlas 2023 | World obesity federation global obesity observatory [Internet]. [cited 2023 Sep 25]. Available from: https://data.worldobesity.org/publications/?cat=19
   Google Scholar
• Horton ES, Silberman C, Davis KL, et al. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care. 2010 Aug;33(8):1759–1765.
   PubMed Web of Science ®Google Scholar
• Padwal R, Li SK, Lau DCW. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev [Internet]. 2004 Oct 20 [cited 2023 Sep 25];2003(3):CD004094. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15266516
   PubMedGoogle Scholar
• Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006 Nov 11;368(9548):1696–1705. doi: 10.1016/S0140-6736(06)69705-5
   PubMed Web of Science ®Google Scholar
• Garvey WT, Birkenfeld AL, Dicker D, et al. Efficacy and safety of liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: the SCALE insulin randomized controlled trial. Diabetes Care [Internet]. 2020 May 1 [cited 2023 Sep 30];43(5):1085–1093. Available from: /pmc/articles/PMC7171937/
   PubMed Web of Science ®Google Scholar
• Drucker DJ. The biology of incretin hormones. Cell Metab. 2006 Mar;3(3):153–165. doi: 10.1016/j.cmet.2006.01.004
   PubMed Web of Science ®Google Scholar
• Curtis L, Holt H, Richardson T, et al. GLP-1 analogue use in patients with sub-optimally controlled type 1 diabetes or obesity improves weight and HbA1c. Pract Diabetes. 2016 Jan 1;33(1):13–17. doi: 10.1002/pdi.1991
   Google Scholar
• Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of Liraglutide in weight management. N Engl J Med [Internet] 2015 Jul 2 [cited 2023 Sep 30];373(1):11–22. Available from: https://pubmed.ncbi.nlm.nih.gov/26132939/
   PubMed Web of Science ®Google Scholar
• Nordisk N, Buse JB, Bain SC, et al. Cardiovascular risk reduction with liraglutide: an exploratory mediation analysis of the LEADER trial. Diabetes Care. 2020;43(7):1546–1552. doi: 10.2337/dc19-2251
   PubMed Web of Science ®Google Scholar
• Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989–1002. doi: 10.1056/NEJMoa2032183
   PubMed Web of Science ®Google Scholar
• Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374(9701):1606–1616. doi: 10.1016/S0140-6736(09)61375-1
   PubMed Web of Science ®Google Scholar
• Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021 Mar 13;397(10278):971–984. doi: 10.1016/S0140-6736(21)00213-0
   PubMed Web of Science ®Google Scholar
• Amaro A, Sugimoto D, Wharton S. Efficacy and safety of semaglutide for weight management: evidence from the STEP program. Postgrad Med [Internet]. 2022 [cited 2023 Nov 4];134(sup1):5–17. Available from: 10.1080/00325481.2022.2147326
   PubMedGoogle Scholar
• Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA [Internet]. 2021 Apr 13 [cited 2023 Oct 26];325(14):1414–1425. Available from: https://jamanetwork.com/journals/jama/fullarticle/2777886
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. For the S 6 I. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844. doi: 10.1056/NEJMoa1607141
   PubMed Web of Science ®Google Scholar
• Irfan IH. Obesity, cardiovascular disease, and the promising role of semaglutide: insights from the SELECT trial. Curr Probl Cardiol. 2024 Jan 1;49(1):102060. doi: 10.1016/j.cpcardiol.2023.102060
   PubMed Web of Science ®Google Scholar
• Medicines Agency E. Human Medicines Division Pharmacovigilance Risk Assessment Committee {PRAC}. 2023 [cited 2023 Oct 31]. Available from: www.ema.europa.eu/contact
   Google Scholar
• Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes [SURMOUNT-2]: a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023 Aug 19 [cited 2023 Oct 26];402(10402):613–626. Available from: http://www.thelancet.com/article/S014067362301200X/fulltext
   PubMed Web of Science ®Google Scholar
• le Roux CW, Zhang S, Aronne LJ, et al. Tirzepatide for the treatment of obesity: rationale and design of the SURMOUNT clinical development program. Obesity (Silver Spring) [Internet]. 2023 Jan 1 [cited 2023 Oct 26];31(1):96. Available from: /pmc/articles/PMC10107501/
   PubMed Web of Science ®Google Scholar
• Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med [Internet]. 2023 Aug 10 [cited 2023 Oct 26];389(6): 514–526. doi: 10.1056/NEJMoa2301972
   PubMed Web of Science ®Google Scholar
• Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet [Internet]. 2023 Aug 26 [cited 2023 Oct 26];402(10403):720–730. Available from: http://www.thelancet.com/article/S0140673623011637/fulltext
   PubMed Web of Science ®Google Scholar
• Medscape Registration [Internet]. [cited 2023 Oct 31]. Available from: https://www.medscape.com/viewarticle/993928?form=fpf
   Google Scholar
• Wharton S, Blevins T, Connery L, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med [Internet]. 2023 Sep 7 [cited 2023 Oct 26];389(10):877–888. doi: 10.1056/NEJMoa2302392
   PubMed Web of Science ®Google Scholar
• Frias JP, Hsia S, Eyde S, et al. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet [Internet]. 2023 Aug 5 [cited 2023 Oct 26];402(10400):472–483. Available from: http://www.thelancet.com/article/S0140673623013028/fulltext
   PubMed Web of Science ®Google Scholar
• Bezin J, Gouverneur A, Enichon MP, et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2023 [cited 2023 Oct 31];46(2):384–390. doi: 10.2337/dc22-1148
   PubMed Web of Science ®Google Scholar
• Sharma A, Parachuri N, Kumar N, et al. Semaglutide and the risk of diabetic retinopathy—current perspective. [cited 2023 Oct 31]. doi: 10.1038/s41433-021-01741-5
   Google Scholar
• Zhang P, Liu Y, Ren Y, et al. The efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysis. Afr Health Sci. 2019 [cited 2023 Sep 30];19(3):2591–2599. doi: 10.4314/ahs.v19i3.35
   PubMed Web of Science ®Google Scholar
• Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Executive summary complete guidelines available at: https://www.aace.com/publications/guidelines. Endocr Pract [Internet]. 2016 Jul 1 [cited 2023 Sep 25];22(7):842–884. Available from: https://pubmed.ncbi.nlm.nih.gov/27472012/
   PubMed Web of Science ®Google Scholar